Moleculin Biotech, Inc. MBRX
8.06 USD -0.60 (-6.93%)
At closeNov 10, 2026, 4:00 PM EST
8.61 +0.55 +6.82%
After hours · Nov 10, 4:00 PM ET
8.01 Day range 8.87
3.31 52-week range 96.20
- YTD
- +143.50%
- 1 year
- -33.22%
News
benzinga.com Moleculin Biotech Reports Preclinical Data Showing Annamycin Plus PD-1 Blockade Extends Survival in Pancreatic Cancer Models Inhibition of CD8+ T cells shortens survival in Annamycin-treated mice, demonstrating the immune system is a functional contributor to Annamycin’s antitumor activity, not a bystanderAnnamycin…
globenewswire.com Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies Inhibition of CD8+ T cells shortens survival in Annamycin-treated mice, demonstrating the immune system is a functional contributor to Annamycin's antitumor activity, not a bystander
benzinga.com Moleculin Reports 43% And 36% Complete Remission Rates In Annamycin Phase 2/3 Trial For Relapsed Or Refractory AML First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AMLMoleculin Biotech, Inc. (NASDAQ:MBRX) ("Moleculin" or the "Company")
globenewswire.com Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AML- benzinga.com Moleculin Biotech Completes Participant Dosing In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company") today announced that dosing has been completed in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in…
globenewswire.com Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027 Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML)
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
globenewswire.com Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial Access the Moleculin CEO Corner here
benzinga.com Moleculin Biotech Announces 1-For-20 Reverse Stock Split, Effective October 20 Filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The…
globenewswire.com Moleculin Announces Reverse Stock Split HOUSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate…
globenewswire.com Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit HOUSTON, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it will present at the upcoming 2026 Maxim Growth Summit in New…- benzinga.com Moleculin Biotech Completes Patient Enrollment In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia Moleculin Biotech, Inc. (NASDAQ:MBRX) ("Moleculin" or the "Company") today announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin…
globenewswire.com Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout HOUSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it has completed and closed enrollment in Part A of its pivotal…
globenewswire.com Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine – Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits
benzinga.com Moleculin Biotech Announces Preclinical Data Showing Annamycin Antitumor Activity In Pancreatic Cancer Is Immune-Mediated Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin’s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside…
globenewswire.com Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin's antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside…
globenewswire.com Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular session. The company's market cap stands at $9.0 million. GRAIL (NASDAQ:GRAL) shares moved upwards by 31.47%…
benzinga.com Dow Surges Over 200 Points; Chicago Fed Activity Index Falls In August U.S. stocks rose Monday, led by the Dow’s 200-point gain; communication shares climbed, energy fell, while oil dropped and Greenland stocks surged.
globenewswire.com Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 110.6% to $1.39 during Friday's regular session. Tenon Medical (NASDAQ:TNON) shares rose 69.71% to $8.99. The company's market cap…
globenewswire.com Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that its pre-recorded presentation from the H.C. Wainwright 28th…
defenseworld.net Moleculin Biotech (NASDAQ:MBRX) Stock Crosses Below Fifty Day Moving Average – Time to Sell? Moleculin Biotech, Inc. (NASDAQ: MBRX - Get Free Report) shares crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $1.21 and traded as low as…
benzinga.com HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Lowers Price Target to $3 HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and lowers the price target from $22 to $3.
globenewswire.com Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference - Video webcast now available here
zacks.com Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).- benzinga.com Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.01) by 38.61 percent. This is a 88.57 percent increase over losses of…
globenewswire.com Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML MIRACLE trial advancing toward planned 90-patient enrollment milestone in…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million. TransCode Therapeutics…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding…
benzinga.com Moleculin Biotech Stock Is Sinking Friday: What's Going On? Moleculin Biotech updates MIRACLE trial for AML and prices a $9.3M offering at $0.75, driving MBRX shares down 63%. Read full data.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding…
globenewswire.com Moleculin Announces Pricing of $9.3 Million Public Offering HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced the pricing of a best-efforts public offering of an aggregate of…
globenewswire.com Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients Prior venetoclax failure - a setting in which published salvage remission rates are approximately 13% and median survival approximately 2. 4 months - shows no adverse impact on blinded composite…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's regular session. The market value of their outstanding shares is at $1.4 million. SciSparc (NASDAQ:SPRC)…
- benzinga.com Moleculin CEO Highlights Preliminary Unblinded Efficacy Results From First 45 Patients Enrolled In Part A Of Pivotal Phase 2/3 MIRACLE Trial Evaluating Annamycin In R/R AML During Investor Segment Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor "What
benzinga.com Why is Moleculin Stock Falling Today? Moleculin reports interim Phase 2/3 trial data as Annamycin shows higher remission rates than control in relapsed or refractory acute myeloid leukemia- benzinga.com Moleculin Biotech Announces Its Data From Phase 2/3 MIRACLE Study For Both Annamycin Treatment Arms Shows Efficacy; Composite Complete Remission Reaches 50%, 57% In Respective Arms Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of the Company's
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular session. Atlantic International (NASDAQ:ATLN) stock rose 143.31% to $1.07. The market value of their…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market session. The company's market cap stands at $5.6 million. Boundless Bio (NASDAQ:BOLD) shares rose 62.85% to…
benzinga.com Moleculin Biotech Enrolls 45th Participant In Its Pivotal Phase 2B/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Relapsed Or Refractory Acute Myeloid Leukemia Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor "What…
benzinga.com Moleculin Biotech Announces That New Data Further Reinforcing The Differentiated Cardiac Safety Profile Of Its Lead Drug Candidate, Annamycin, Was Presented At The American Society Of Clinical Oncology Annual Meeting The poster presentation, titled "Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis," highlighted findings from a pooled analysis across five completed clinical…- benzinga.com Moleculin Biotech Q1 EPS $(3.54) Misses $(1.57) Estimate Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(3.54) per share which missed the analyst consensus estimate of $(1.57) by 125.48 percent. This is a 77.59 percent increase over losses…
benzinga.com Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding Moleculin Biotech nears first MIRACLE trial data unblinding as Annamycin shows higher remission rates in relapsed AML patients.
benzinga.com Moleculin Announces Data From Phase 2B/3 "MIRACLE" Trial Evaluating Annamycin In Combination With Cytarabine Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of careFirst 45-subject data unblinding expected before June 30,…- benzinga.com Moleculin Biotech Announces Publication Of An Abstract At The European Hematology Association Congress That Highlights The Cardiac Safety Profile Of Annamycin The abstract titled, "Cardiac Safety of L-Annamycin Across High Cumulative Anthracycline Exposure: Implications for Relapsed/Refractory AML," will highlight pooled cardiac safety findings from five…
- benzinga.com Moleculin Biotech Announces Significant Advancement In IP Portfolio With Issuance Of Hong Kong Patent Covering Proprietary Method Of Reconstituting Liposomal Annamycin Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data ReleaseHOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $22 Price Target HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $22 price target.